Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 79
Selected: 0
NCT IDTitle
NCT00655733Phase II Study of HMPL-004 in Subjects With Crohn's Disease
NCT04755075Surufatinib Hepatic Impairment Study
NCT05015608Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT02966171A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
NCT03160833A Study of HMPL-453 in Patients With Advanced Solid Malignancies
NCT02133157Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
NCT05509699Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
NCT02966821Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
NCT02689752A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib
NCT02588170Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
NCT02601248Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT06437353Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
NCT01882764HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
NCT03483259To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
NCT05511051A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
NCT02503033A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT05522738Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
NCT02601274Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT02017236A Food Effect Phase I Study of the Volitinib in Healthy Subjects
NCT02631642A Study of HMPL-689 in Healthy Volunteers
NCT04923945Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
NCT04557397Fruquintinib CYP3A Inhibitor and Inducer Study
NCT04272957A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
NCT02415023A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer
NCT04849351Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
NCT02614495Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
NCT02252913A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer
NCT02976116A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
NCT04923932Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
NCT03091192Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03860948A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers
NCT04716634Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
NCT01975077A Phase Ib Study of Fruquintinib in 3rd Line mCRC
NCT01773018Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT03223376A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
NCT03251378A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
NCT04510649Surufatinib DDI With a PPI and a CYP3A Inducer
NCT03483948Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
NCT04755088Surufatinib Renal Impairment Study
NCT02105129A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
NCT05277454Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
NCT04372394A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects
NCT03860532Phase I Clinical Trial in Healthy Male Volunteers
NCT03231501HMPL-813 in Treating Patients With Glioblastoma
NCT05009836Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
NCT01645215Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors
NCT03778229Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT01985555Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT03873532A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients